The short version of lyophilized peptide fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-15 and is reviewed periodically as new material appears.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue peptide | GHRH analog backbone |
| Approximate molecular mass | 5136 Da | Varies with counterion and hydration state |
| N-terminal group | trans-3-hexenoyl | Increases resistance to dipeptidyl peptidase IV |
| Primary receptor | GHRH receptor (GHRHR) | Class B G protein-coupled receptor on somatotrophs |
| Principal mediator | IGF-1 | Rises indirectly after growth hormone release |
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Amputation is the removal of a limb or other body part by trauma, medical illness, or surgery. As a surgical measure, it is used to control pain or a disease process in the affected limb, such as malignancy or gangrene. In some cases, it is carried out on individuals as a preventive surgery for such problems. A special case is that of congenital amputation, a congenital disorder, where fetal limbs have been cut off by constrictive bands. In some countries, judicial amputation is currently used to punish people who commit crimes. Amputation has also been used as a tactic in war and acts of terrorism; it may also occur as a war injury. In some cultures and religions, minor amputations or mutilations are considered a ritual accomplishment. When done by a person, the person executing the amputation is an amputator. The oldest evidence of this practice comes from a skeleton found buried in Liang Tebo cave, East Kalimantan, Indonesian Borneo dating back to at least 31,000 years ago, where it was done when the amputee was a young child. A prosthesis or a bioelectric replantation may restore sensation of the amputated limb.
Mueller–Hinton agar is a type of growth medium used in microbiology to culture bacterial isolates and test their susceptibility to antibiotics. This medium was first developed in 1941 by John Howard Mueller and Jane Hinton, who were microbiologists working at Harvard University. However, Mueller–Hinton agar is made up of a couple of components, including beef extract, acid hydrolysate of casein, and starch, as well as agar to solidify the mixture. The composition of Mueller–Hinton agar can vary depending on the manufacturer and the intended use, but the medium is generally nutrient-rich and free of inhibitors that could interfere with bacterial growth.
In March 1956, after the 20th Congress of the Communist Party of the Soviet Union in Moscow ushered in de-Stalinization, Edward Ochab was chosen to replace the deceased Bolesław Bierut as first secretary of the Polish United Workers' Party. As a result, Poland was rapidly overtaken by social restlessness and reformist undertakings; thousands of political prisoners were released and many people previously persecuted were officially rehabilitated. Worker riots in Poznań in June 1956 were violently suppressed, but they gave rise to the formation of a reformist current within the communist party. Amidst the continuing social and national upheaval, a further shakeup took place in the party leadership as part of what is known as the Polish October of 1956.[k] While retaining most traditional communist economic and social aims, the state under Władysław Gomułka, the new first secretary of the PZPR, liberalized internal life in Poland. The dependence on the Soviet Union was somewhat mollified, and the state's relationships with the Church and Catholic lay activists were put on a new footing. A repatriation agreement with the Soviet Union allowed the repatriation of hundreds of thousands of Poles who were still in Soviet hands, including many former political prisoners. Collectivization efforts were abandoned—agricultural land, unlike in other Comecon countries, remained for the most part in the private ownership of farming families. State-mandated provisions of agricultural products at fixed, artificially low prices were reduced, and from 1972 eliminated.
White Castle also markets its sandwiches in 20 or 30-hamburger boxes, called a Crave Clutch or Crave Case, respectively. The figure of 30 burgers represents the number that can be produced on one of its standard griddles at the same time. A "Crave Crate" is also offered, with the contents being 100 burgers. To celebrate its 100th year in operation, White Castle re-introduced their original burger, called the 1921 Slider. It features an addition of lettuce, tomato, and caramelized onions. Typically normal sliders have 5 holes in the patty while cooking on a griddle of onions and water to steam the sliders to completion. The 1921 is grilled directly on the griddle instead. A variety of White Castle products (mostly frozen) are also sold in grocery stores. Some locations had been cobranded with Church's Chicken until that co-branding arrangement ended around 2010. Around 2012, White Castle experimented with the Laughing Noodle brand that was to share space with White Castle restaurants. The Laughing Noodle concept was discarded a few years later. The Laughing Noodle brand was developed to offer supplemental variety to a White Castle Restaurant. At least one such location was constructed and operated in Sharonville, Ohio. Although White Castle originated in Wichita, Kansas, the city has not had a restaurant since 1938, nor is there a White Castle restaurant in the entire state of Kansas. White Castle is one of the few restaurant chains that does not have a location in its original city.
=== Location === Lower Saxony has a natural boundary in the north in the North Sea and the lower and middle reaches of the River Elbe, although parts of the city of Hamburg lie south of the Elbe. The state and city of Bremen is an enclave entirely surrounded by Lower Saxony. The Bremen/Oldenburg Metropolitan Region is a cooperative body for the enclave area. To the southeast, the state border runs through the Harz, low mountains that are part of the German Central Uplands. The northeast and west of the state, which form roughly three-quarters of its land area, belong to the North German Plain, while the south is in the Lower Saxon Hills, including the Weser Uplands, Leine Uplands, Schaumburg Land, Brunswick Land, Untereichsfeld, Elm, and Lappwald. In the northeast of Lower Saxony is the Lüneburg Heath. The heath is dominated by the poor, sandy soils of the geest, while in the central-east and southeast in the loess börde zone, productive soils with high natural fertility occur. Under these conditions—with loam and sand-containing soils—the land is well-developed agriculturally. In the west lie the County of Bentheim, Osnabrück Land, Emsland, Oldenburg Land, Ammerland, Oldenburg Münsterland, and on the coast East Frisia.
Sources: en.wikipedia.org
Central obesity can be a feature of lipodystrophies, a group of diseases that is either inherited, or due to secondary causes (often protease inhibitors, a group of medications against AIDS). Central obesity is a symptom of Cushing's syndrome and is also common in patients with polycystic ovary syndrome (PCOS). Central obesity is associated with glucose intolerance and dyslipidemia. Once dyslipidemia becomes a severe problem, an individual's abdominal cavity would generate elevated free fatty acid flux to the liver. The effect of abdominal adiposity occurs not just in those who are obese, but also affects people who are non-obese and it also contributes to insulin sensitivity. Ghroubi et al. (2007) examined whether abdominal circumference is a more reliable indicator than BMI or the presence of knee osteoarthritis in obese patients. They found that it actually appears to be a factor linked with the presence of knee pain as well as osteoarthritis in obese study subjects. Ghroubi et al. (2007) concluded that a high abdominal circumference is associated with great functional repercussion. Research published in The Lancet (2023) found that high levels of visceral fat were related to poorer cognitive performance. The findings suggest that maintaining a healthy weight and metabolic health may be important for preserving cognitive function.
TDS spectrum 1 and 2 are typical examples of a TPD measurement. Both are examples of NO desorbing from a single crystal in high vacuum. The crystal was mounted on a titanium filament and heated with current. The desorbing NO was measured using a mass spectrometer monitoring the atomic mass of 30. Before 1990 analysis of a TPD spectrum was usually done using a so-called simplified method; the "Redhead" method, assuming the exponential prefactor and the desorption energy to be independent of the surface coverage. After 1990 and with use of computer algorithms TDS spectra were analyzed using the "complete analysis method" or the "leading edge method". These methods assume the exponential prefactor and the desorption energy to be dependent of the surface coverage. Several available methods of analyzing TDS are described and compared in an article by A.M. de JONG and J.W. NIEMANTSVERDRIET. During parameter optimization/estimation, using the integral has been found to create a more well behaved objective function than the differential.
Researchers in the field have developed approaches to produce living organs that are constructed with the appropriate biological and mechanical properties. 3D bioprinting is based on three main approaches: biomimicry, autonomous self-assembly and mini-tissue building blocks. The first approach of bioprinting is called biomimicry. The main goal of this approach is to create fabricated structures that are identical to the natural structure that are found in the tissues and organs in the human body. Biomimicry requires duplication of the shape, framework, and the microenvironment of the organs and tissues. The application of biomimicry in bioprinting involves creating both identical cellular and extracellular parts of organs. For this approach to be successful, the tissues must be replicated on a micro scale. Therefore, it is necessary to understand the microenvironment, the nature of the biological forces in this microenvironment, the precise organization of functional and supporting cell types, solubility factors, and the composition of extracellular matrix.
He made one of his final TV appearances during season 5 on Oprah: Where Are They Now? He voiced characters in the television series Captain Planet and the Planeteers, Fish Police, and Happily Ever After: Fairy Tales for Every Child. He was known for the voice of Rafiki in the movie The Lion King and its sequels and spin-offs. He lent his deep tenor voice as Mr. Thicknose in The Land Before Time VIII: The Big Freeze. He also supplied the voice for Eli Vance in the 2004 video game Half-Life 2 and its episodic sequels.
Sources: en.wikipedia.org
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.
Growth hormone released from the pituitary stimulates IGF-1 production in the liver and other tissues, so circulating IGF-1 generally rises during exposure. The size of the rise varies between individuals and depends on baseline hormonal status and other concurrent factors.
Reported imaging studies focus on visceral adipose tissue, where reductions are more consistently observed across trials. Subcutaneous depots show smaller and less reproducible changes, so the two compartments should not be treated as equivalent.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.